blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3134082

EP3134082 - MODIFICATION OF EXTRACORPOREAL PHOTOPHERESIS TECHNOLOGY WITH PORPHYRIN PRECURSORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.04.2022
Database last updated on 26.06.2024
FormerThe patent has been granted
Status updated on  30.04.2021
FormerGrant of patent is intended
Status updated on  21.12.2020
FormerExamination is in progress
Status updated on  08.09.2017
FormerRequest for examination was made
Status updated on  27.01.2017
FormerThe international publication has been made
Status updated on  18.11.2016
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Oslo Universitetssykehus HF
Sognsvannsveien 20
0372 Oslo / NO
[2017/09]
Inventor(s)01 / PENG, Qian
Baerumsveien 24B
N-0284 Oslo / NO
02 / WARLOE, Trond
Heggelibakken 6
0375 Oslo / NO
03 / NESLAND, Jahn M.
Bleikerveien 61
1387 Asker / NO
04 / CHRISTENSEN, Eidi
Merkurveien 11A
7036 Trondheim / NO
05 / GEDERAAS, Odrun Arna
Værestranda 74
7054 Ranheim / NO
06 / HOLIEN, Toril
Osvegen 19B
7054 Ranheim / NO
 [2019/52]
Former [2017/09]01 / PENG, Qian
Baerumsveien 24B
N-0284 Oslo / NO
Representative(s)Zacco GmbH
Bayerstrasse 83
80335 München / DE
[2017/09]
Application number, filing date15718489.624.04.2015
[2017/09]
WO2015EP58986
Priority number, dateGB2014000729624.04.2014         Original published format: GB 201407296
[2017/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015162279
Date:29.10.2015
Language:EN
[2015/43]
Type: A1 Application with search report 
No.:EP3134082
Date:01.03.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 29.10.2015 takes the place of the publication of the European patent application.
[2017/09]
Type: B1 Patent specification 
No.:EP3134082
Date:02.06.2021
Language:EN
[2021/22]
Search report(s)International search report - published on:EP29.10.2015
ClassificationIPC:A61K31/197, A61K41/00, A61K31/22, A61P35/02, A61P37/02
[2017/09]
CPC:
A61K31/197 (EP,KR,US); A61K31/409 (GB); A61K35/14 (US);
A61K31/195 (GB); A61K31/22 (EP,KR,US); A61K31/37 (GB);
A61K41/0061 (EP,KR,US); A61K41/0066 (US); A61P11/00 (EP);
A61P25/00 (EP); A61P29/00 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P43/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/09]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:MODIFIKATION DER EXTRAKORPORALEN PHOTOPHERESE TECHNOLOGIE MIT PORPHYRIN-VORLÄUFERN[2020/52]
English:MODIFICATION OF EXTRACORPOREAL PHOTOPHERESIS TECHNOLOGY WITH PORPHYRIN PRECURSORS[2017/09]
French:MODIFICATION DE LA PHOTOPHÉRÈSE EXTRACORPORELLE AVEC LES PRÉCURSEURS DE LA PORPHYRINE[2020/52]
Former [2017/09]MODIFIZIERUNG VON EXTRAKORPORALER PHOTOPHERESETECHNOLOGIE MIT PORPHYRINVORLÄUFERN
Former [2017/09]MODIFICATION DE LA TECHNOLOGIE DE PHOTOPHÉRÈSE EXTRACORPORELLE À L'AIDE DE PRÉCURSEURS DE PORPHYRINE
Entry into regional phase18.11.2016National basic fee paid 
18.11.2016Designation fee(s) paid 
18.11.2016Examination fee paid 
Examination procedure18.11.2016Examination requested  [2017/09]
18.11.2016Date on which the examining division has become responsible
26.06.2017Amendment by applicant (claims and/or description)
07.09.2017Despatch of a communication from the examining division (Time limit: M06)
07.03.2018Reply to a communication from the examining division
25.10.2018Despatch of a communication from the examining division (Time limit: M06)
26.04.2019Reply to a communication from the examining division
24.07.2019Despatch of a communication from the examining division (Time limit: M06)
28.01.2020Reply to a communication from the examining division
22.12.2020Communication of intention to grant the patent
30.03.2021Fee for grant paid
30.03.2021Fee for publishing/printing paid
30.03.2021Receipt of the translation of the claim(s)
Opposition(s)03.03.2022No opposition filed within time limit [2022/19]
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
24.04.2018Renewal fee patent year 04
25.04.2019Renewal fee patent year 05
09.03.2020Renewal fee patent year 06
27.04.2021Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.04.2015
AL02.06.2021
AT02.06.2021
CY02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
MC02.06.2021
MK02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
TR02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
[2024/29]
Former [2024/22]HU24.04.2015
AL02.06.2021
AT02.06.2021
CY02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
MC02.06.2021
MK02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2024/20]HU24.04.2015
AL02.06.2021
AT02.06.2021
CY02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
MC02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2024/18]HU24.04.2015
AL02.06.2021
AT02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
MC02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2023/06]AL02.06.2021
AT02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
MC02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2022/29]AL02.06.2021
AT02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SI02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2022/26]AL02.06.2021
AT02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2022/21]AT02.06.2021
CZ02.06.2021
DK02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2022/10]AT02.06.2021
CZ02.06.2021
EE02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
IS02.10.2021
PT04.10.2021
Former [2022/09]AT02.06.2021
CZ02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
NL02.06.2021
PL02.06.2021
RO02.06.2021
RS02.06.2021
SE02.06.2021
SK02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
PT04.10.2021
Former [2022/07]AT02.06.2021
FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
NL02.06.2021
PL02.06.2021
RS02.06.2021
SE02.06.2021
SM02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
Former [2021/52]FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
PL02.06.2021
RS02.06.2021
SE02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
Former [2021/51]FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
RS02.06.2021
SE02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
Former [2021/49]FI02.06.2021
HR02.06.2021
LT02.06.2021
LV02.06.2021
SE02.06.2021
BG02.09.2021
NO02.09.2021
GR03.09.2021
Former [2021/47]FI02.06.2021
LT02.06.2021
BG02.09.2021
Former [2021/46]FI02.06.2021
LT02.06.2021
Cited inInternational search[XPI]  - CUNDERLÍKOVÁ B ET AL, "Modification of extracorporeal photopheresis technology with porphyrin precursors. Comparison between 8-methoxypsoralen and hexaminolevulinate in killing human T-cell lymphoma cell lines in vitro", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - GENERAL SUBJECTS, ELSEVIER, AMSTERDAM, NL, (20140608), vol. 1840, no. 9, doi:10.1016/J.BBAGEN.2014.05.020, ISSN 0304-4165, pages 2702 - 2708, XP029015600 [XP] 1-15 * abstract * * figure 5 * [I] 1-15

DOI:   http://dx.doi.org/10.1016/j.bbagen.2014.05.020
 [Y]  - DAVID M. WARD, "Extracorporeal photopheresis: How, when, and why", JOURNAL OF CLINICAL APHERESIS, (20110101), vol. 26, no. 5, doi:10.1002/jca.20300, ISSN 0733-2459, pages 276 - 285, XP055198103 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1002/jca.20300
 [Y]  - SUSAN SHAHZIDI ET AL, "Simultaneously targeting mitochondria and endoplasmic reticulum by photodynamic therapy induces apoptosis in human lymphoma cells", PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, (20110101), vol. 10, no. 11, doi:10.1039/c1pp05169e, ISSN 1474-905X, page 1773, XP055198088 [Y] 1-15 * paragraph entitled "1 Introduction"; paragraph entitled "2.4 Photodynamic treatment with HAL"; figure 2 *

DOI:   http://dx.doi.org/10.1039/c1pp05169e
 [A]  - QIAN PENG, "Editorial: Photodynamic Therapy and Detection", JOURNAL OF ENVIRONMENTAL PATHOLOGY, TOXICOLOGY AND ONCOLOGY, (20060101), vol. 25, no. 1-2, doi:10.1615/JEnvironPatholToxicolOncol.v25.i1-2.10, ISSN 0731-8898, pages 1 - 6, XP055198212 [A] 1-15 * page 2, line 1-14 *

DOI:   http://dx.doi.org/10.1615/JEnvironPatholToxicolOncol.v25.i1-2.10
 [Y]  - N F GAMALEIA, "Sensitivity of normal and malignant human lymphocytes to 5-aminolevulinic acidmediated photodynamic damage", EXP ONCOL, (20080301), vol. 30, no. 1, pages 65 - 69, XP055198270 [Y] 1-15 * table 1-3 *
 [Y]  - H.PETER VAN IPEREN ET AL, "Singlet oxygen producing photosensitizers in photophoresis", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, (19970401), vol. 38, no. 2-3, doi:10.1016/S1011-1344(96)07442-8, ISSN 1011-1344, pages 203 - 208, XP055197966 [Y] 1-15 * abstract; table 1 and 3 *

DOI:   http://dx.doi.org/10.1016/S1011-1344(96)07442-8
ExaminationEP0196515
 US5030200
 FR2696756
 WO2005004862
    - Zale P Bernstein, "Photopheresis in HIV-1 Infected Patients (Pt) Using Benzoporphyrin Derivative (BPD-MA) Induces Apoptosis in CD4 Cells, Increases Cytolytic T-Cell Activity, Intracellular Expression of Chemokines, and Decreases HIV Infectivity and Viral Load.", Blood, (20060101), vol. 108, no. 11, XP055197891
    - BERNSTEIN ZALE P ET AL, "Photopheresis in HIV-1 infected patients using Benzoporphyrin derivative (BPD-MA) and light induces apoptosis in CD4 cells and decreases HIV infectivity", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (20011116), Database accession no. PREV200200241389
    - BLOOD, 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, (20011116), vol. 98, no. 11 Part 1, ISSN 0006-4971, page 508a
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.